Another study of Boeri et al. displayed that a miRNA signature classifier (MSC) composed of 24 miRNAs could distinguish NSCLC patients (n = 140) that would benefit from anti PD-L1 immunotherapy from patients who would not. The gene discussed is CD274; the disease is non-small cell lung carcinoma.